Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback